Baxter Healthcare Corporation

Baxter Healthcare Corporation
Share

Baxter is the world’s leading manufacturer of commercially prepared IV solutions as well as frozen and ready-to-use premixed drugs in flexible IV containers. Baxter’s portfolio of IV solutions and premixed drugs is the broadest in the industry. IV infusion pumps and administration sets control the delivery of IV fluids and drugs to patients.

Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number and composition of the foreign material, and the patient’s underlying medical condition. In the absence of in-line filtration, these particles may cause local vein irritation...

Helps ensure safer drug preparation, transportation, administration and disposal
Helps support compliance with NIOSH and upcoming standards
DEERFIELD, Ill., January 11, 2018 – Baxter International Inc. (NYSE: BAX), a leader in innovative technology for medication delivery, today announced a distribution agreement for the U.S. launch of the...

Proposed acquisition includes two pioneering hemostat and sealant products, including the first and only stand-alone recombinant thrombin and a surgical sealant Products expand Baxter's portfolio of surgical solutions to address intraoperative bleeding and increase surgeons' options
DEERFIELD, Ill., JANUARY 8, 2018 – Baxter International Inc....

Baxter Healthcare Corporation

 •  December 5, 2017

DEERFIELD, Ill., December 4, 2017 — Baxter International Inc. (NYSE: BAX) will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017, in New York at 11:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation, along with accompanying slides, can be accessed at...

Baxter Healthcare Corporation

 •  November 15, 2017

DEERFIELD, Ill., November 14, 2017 – Baxter International Inc. announced today it is voluntarily recalling one lot of NEXTERONE (amiodarone HCl) 150 mg/100 mL Premixed Injection – distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities – due to the potential presence of particulate...

Baxter Healthcare Corporation

 •  November 15, 2017

DEERFIELD, Ill., November 14, 2017 — Baxter International Inc. (NYSE: BAX) will present at the Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 7:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation can be accessed at...

Baxter Healthcare Corporation

 •  November 7, 2017

New data identify a potential role for SHARESOURCE remote patient management in earlier identification of peritonitis Additional data show how the remote patient management platform may help detect potential catheter dysfunction SHARESOURCE platform has helped healthcare providers remotely manage more than 1 million PD treatments globally NEW...

Baxter Healthcare Corporation

 •  November 3, 2017

Data spotlights innovations and therapeutic practices focused on the best possible outcomes for dialysis patients NEW ORLEANS, NOV. 2, 2017 – Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced the presentation of 27 abstracts at the American Association of Nephrology (ASN) Kidney Week, Oct. 31 - Nov. 5, to...

Baxter Healthcare Corporation

 •  October 17, 2017

DEERFIELD, Ill., October 16, 2017 — Baxter International Inc. (NYSE: BAX) will present at the 26th Annual Credit Suisse Healthcare Conference on Tuesday, November 7, 2017, in Scottsdale, Ariz. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 2:10 p.m. Mountain Time. The live webcast of Baxter’s presentation can be accessed...

Baxter Healthcare Corporation

 •  October 5, 2017

DEERFIELD, Ill., October 5, 2017 – Baxter International Inc. announced today it is voluntarily recalling one shipment from a single lot of INTRALIPID 20% IV Fat Emulsion, 100 mL, distributed between 8/11/17 and 8/31/17 to hospitals and healthcare providers in the United States, to the user level. The product has been exposed to subfreezing...